Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Statement on Measles-Mumps-Rubella-Varicella Vaccine: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Literature DB >> 31682661

Statement on Measles-Mumps-Rubella-Varicella Vaccine: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)^†.

Ben Tan, Shainoor Ismail.

Abstract

Year: 2010 PMID： 31682661 PMCID： PMC6802435 DOI： 10.14745/ccdr.v36i00a09

Source DB: PubMed Journal: Can Commun Dis Rep ISSN： 1188-4169

× No keyword cloud information.

23 in total

1. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Authors: Markus Knuf; Pirmin Habermehl; Fred Zepp; Wilma Mannhardt; Martin Kuttnig; Pekka Muttonen; Albrecht Prieler; Hartwig Maurer; Helmtrud Bisanz; Nadia Tornieporth; Dominique Descamps; Paul Willems
Journal: Pediatr Infect Dis J Date: 2006-01 Impact factor: 2.129

2. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.

Authors: Timo Vesikari; Maija Baer; Paul Willems
Journal: Pediatr Infect Dis J Date: 2007-02 Impact factor: 2.129

3. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.

Authors: Volker Schuster; Walter Otto; Lothar Maurer; Patricia Tcherepnine; Ulrich Pfletschinger; Klaus Kindler; Peter Soemantri; Uta Walther; Ute Macholdt; Martine Douha; Patrice Pierson; Paul Willems
Journal: Pediatr Infect Dis J Date: 2008-08 Impact factor: 2.129

4. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Authors: Terry Nolan; Peter McIntyre; Don Roberton; Dominique Descamps
Journal: Vaccine Date: 2002-12-13 Impact factor: 3.641

5. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.

Authors: P Goh; F S Lim; H H Han; P Willems
Journal: Infection Date: 2007-08-20 Impact factor: 3.553

6. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.

Authors: Scott A Halperin; Giuseppe Ferrera; David Scheifele; Gerald Predy; Giuseppe Stella; Mario Cuccia; Martine Douha; Paul Willems
Journal: Vaccine Date: 2009-02-24 Impact factor: 3.641

7. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: Mona Marin; Dalya Güris; Sandra S Chaves; Scott Schmid; Jane F Seward
Journal: MMWR Recomm Rep Date: 2007-06-22

8. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.

Authors: Steven J Jacobsen; Bradley K Ackerson; Lina S Sy; Trung N Tran; Tonia L Jones; Janis F Yao; Fagen Xie; T Craig Cheetham; Patricia Saddier
Journal: Vaccine Date: 2009-06-09 Impact factor: 3.641

9. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.

Authors: Markus Knuf; Fred Zepp; Claudius U Meyer; Pirmin Habermehl; Lothar Maurer; Hanns-Michael Burow; Ulrich Behre; Michel Janssens; Paul Willems; Helmtrud Bisanz; Volker Vetter; Ruprecht Schmidt-Ott
Journal: Eur J Pediatr Date: 2010-02-11 Impact factor: 3.860